Trials in New Jersey.

This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…

This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…

This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…

This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…

This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…

This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…

This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…

This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…

This is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…

This trial tests sabirnetug, an antibody given by IV infusion every four weeks, against placebo. It looks at whether the drug slows decline in thinking and…

This trial tests whether a daily dose of alpha-linolenic acid (ALA), a plant-based omega-3 found in flaxseed oil, affects memory and thinking, and the health…

This Phase 2 trial is testing SAR448851, a once-daily oral pill, in people with early Alzheimer's disease who have confirmed amyloid buildup in the brain.…

This postmarketing study looks at how well LEQEMBI (lecanemab), an anti-amyloid antibody already approved in Canada, slowed changes in thinking and daily…

This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…

This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…

This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…

This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. It looked at how well the…

This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. Researchers measured safety…

This trial tested SB-742457, an experimental drug added on top of donepezil, the standard Alzheimer's medication, in people with mild-to-moderate Alzheimer's…

This trial looked at the long-term safety and tolerability of bapineuzumab, an antibody drug given by infusion, in people with Alzheimer's who had finished an…

This trial tests whether a more precise form of whole-brain radiation can spare the hippocampus, the brain's memory center, in people whose cancer has spread…

Enroll-HD is an observational study, meaning no drug or treatment is given. It follows people with Huntington's disease, and their relatives and controls,…

This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…

This study looks at whether a blood test can spot aggressive B-cell lymphoma coming back after first-round chemotherapy. The test reads tumor DNA left in the…

This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…

This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…

This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…

This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…

This trial tests a device called the GammaSense Stimulation System, which delivers sensory stimulation at a specific brain rhythm frequency called gamma.…

This study records biological signals from the nervous system while participants perform everyday movements like walking and pointing, and practice slow…

This trial is testing three versions of a behavioral therapy called Functional Communication Training, or FCT, which teaches children with severe problem…

This trial is testing NYX-458, an experimental oral drug, against a placebo in people who have mild cognitive impairment or mild dementia caused by Parkinson's…

This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…

This trial tests donanemab, an anti-amyloid antibody given by infusion, against a placebo in people with no memory or thinking problems but signs of amyloid in…

This study compares two group wellness classes to see which one better supports long-term wellbeing. Participants are people living with a brain injury or…

This pilot study is testing a wearable device that delivers pulsed electromagnetic fields to the brain in people who already have mild to moderate Alzheimer's…

This trial tests whether a structured memory retraining program helps older adults with amnestic mild cognitive impairment (MCI) learn and remember new…

This trial is testing whether masupirdine, a daily pill, can ease agitation in people who already have Alzheimer's dementia. Agitation can mean restlessness,…

This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…

This trial tests whether a pill called AR1001 can slow memory and thinking decline in people with early Alzheimer's, compared with a placebo. It also checks…

This trial is testing a behavioral therapy approach for children ages 3 to 17 who have persistent problem behaviors like aggression or self-injury. Researchers…

This trial is comparing two exercise programs in older African Americans: a cardio-dance fitness class versus a strength, flexibility, and balance program.…

This trial is testing AV-1959D, a vaccine designed to prompt the immune system to target amyloid beta — the protein that builds up in Alzheimer's disease. It…

This Phase 3 trial is testing whether different dosing schedules of donanemab — an anti-amyloid antibody already conditionally approved — can reduce the rate…

This trial studies behavioral therapy techniques for children with severe problem behaviors like aggression and self-injury. Researchers are testing whether…

This trial is testing a standardized behavioral treatment manual for children ages 3 to 17 who have serious challenging behaviors like aggression or…

This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…

This Phase 2 trial is testing two doses of an experimental drug called GSK4527226 against a placebo in people with early Alzheimer's disease, including those…

This trial tests whether a once-daily 10 mg pill called Xanamem can safely affect thinking and daily function in people who already have mild or moderate…

This trial is testing SNK01, an infusion made from a person's own natural killer immune cells, in people with moderate Alzheimer's. It is given through an IV…